INR 572.8
(0.93%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.07 Billion INR | -47.37% |
2022 | 1.88 Billion INR | 18.03% |
2021 | 1.6 Billion INR | 17.49% |
2020 | 1.36 Billion INR | 2.93% |
2019 | 1.32 Billion INR | 11.18% |
2018 | 1.19 Billion INR | 4.41% |
2017 | 1.13 Billion INR | 40.25% |
2016 | 812.63 Million INR | 19.6% |
2015 | 679.45 Million INR | 29.27% |
2014 | 525.59 Million INR | 11.94% |
2013 | 469.52 Million INR | 2.55% |
2012 | 457.83 Million INR | -0.9% |
2011 | 461.97 Million INR | 6.14% |
2010 | 435.24 Million INR | 15.84% |
2009 | 375.71 Million INR | 6208.19% |
2008 | 5.95 Million INR | -12.58% |
2007 | 6.81 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 252.91 Million INR | 13.89% |
2023 Q4 | 254.8 Million INR | 9.54% |
2023 FY | 994.01 Million INR | -47.37% |
2023 Q1 | 536.02 Million INR | 7.78% |
2023 Q2 | 535.92 Million INR | -0.02% |
2023 Q3 | 232.61 Million INR | -56.6% |
2022 Q2 | 465.41 Million INR | -1.48% |
2022 Q3 | 453.57 Million INR | -2.54% |
2022 Q4 | 497.33 Million INR | 9.65% |
2022 Q1 | 472.42 Million INR | 32.83% |
2022 FY | 1.88 Billion INR | 18.03% |
2021 Q4 | 355.66 Million INR | -16.89% |
2021 FY | 1.6 Billion INR | 17.49% |
2021 Q1 | 414.41 Million INR | 35.61% |
2021 Q2 | 402.13 Million INR | -2.96% |
2021 Q3 | 427.95 Million INR | 6.42% |
2020 Q3 | 350.87 Million INR | -7.76% |
2020 Q2 | 380.41 Million INR | 17.03% |
2020 Q1 | 325.06 Million INR | 38.28% |
2020 Q4 | 305.59 Million INR | -12.91% |
2020 FY | 1.36 Billion INR | 2.93% |
2019 Q3 | 382.97 Million INR | 11.87% |
2019 Q4 | 235.08 Million INR | -38.62% |
2019 FY | 1.32 Billion INR | 11.18% |
2019 Q1 | 362.71 Million INR | 109.07% |
2019 Q2 | 342.35 Million INR | -5.62% |
2018 Q1 | 334.16 Million INR | -2.28% |
2018 Q4 | 173.49 Million INR | -51.95% |
2018 Q2 | 321.35 Million INR | -3.84% |
2018 Q3 | 361.04 Million INR | 12.35% |
2018 FY | 1.19 Billion INR | 4.41% |
2017 Q3 | 267.14 Million INR | -2.77% |
2017 FY | 1.13 Billion INR | 40.25% |
2017 Q4 | 341.95 Million INR | 28.0% |
2017 Q2 | 274.75 Million INR | 10.61% |
2017 Q1 | 248.4 Million INR | 11.71% |
2016 FY | 812.63 Million INR | 19.6% |
2016 Q3 | 256.48 Million INR | -11.17% |
2016 Q2 | 288.72 Million INR | 33.08% |
2016 Q1 | 216.95 Million INR | 34.65% |
2016 Q4 | 222.35 Million INR | -13.31% |
2015 Q3 | 170.5 Million INR | -7.14% |
2015 Q1 | 168.93 Million INR | 62.27% |
2015 FY | 679.45 Million INR | 29.27% |
2015 Q2 | 183.61 Million INR | 8.69% |
2015 Q4 | 161.12 Million INR | -5.5% |
2014 Q2 | 143.91 Million INR | 9.74% |
2014 Q4 | 104.1 Million INR | -28.9% |
2014 Q3 | 146.43 Million INR | 1.75% |
2014 Q1 | 131.14 Million INR | 30.05% |
2014 FY | 525.59 Million INR | 11.94% |
2013 Q3 | 108.69 Million INR | -24.2% |
2013 Q1 | 116.61 Million INR | 75.84% |
2013 Q2 | 143.38 Million INR | 22.96% |
2013 Q4 | 100.84 Million INR | -7.22% |
2013 FY | 469.52 Million INR | 2.55% |
2012 Q4 | 66.31 Million INR | -53.88% |
2012 Q3 | 143.8 Million INR | 9.08% |
2012 Q2 | 131.83 Million INR | 13.75% |
2012 Q1 | 115.89 Million INR | 115.99% |
2012 FY | 457.83 Million INR | -0.9% |
2011 Q3 | 161.72 Million INR | 0.0% |
2011 FY | 461.97 Million INR | 6.14% |
2011 Q4 | 53.65 Million INR | -66.82% |
2010 FY | 435.24 Million INR | 15.84% |
2009 FY | 375.71 Million INR | 6208.19% |
2008 FY | 5.95 Million INR | -12.58% |
2008 Q4 | 5.8 Million INR | 0.0% |
2007 FY | 6.81 Million INR | 0.0% |
2007 Q4 | -4.36 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amrutanjan Health Care Limited | 2.09 Billion INR | 48.703% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -15650.528% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 50.601% |
FDC Limited | 3.49 Billion INR | 69.307% |
Gufic Biosciences Limited | 1.18 Billion INR | 9.473% |
Hikal Limited | 4.46 Billion INR | 75.936% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 49.431% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 51.196% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -160.455% |
Medico Remedies Limited | 59.67 Million INR | -1700.06% |
Nectar Lifesciences Limited | 932.7 Million INR | -15.17% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -1742.893% |
RPG Life Sciences Limited | 1.63 Billion INR | 34.321% |
Sequent Scientific Limited | 2.9 Billion INR | 62.982% |
Shilpa Medicare Limited | 3.33 Billion INR | 67.783% |
Sigachi Industries Limited | 579.88 Million INR | -85.241% |
Themis Medicare Limited | 1.12 Billion INR | 4.584% |
Unichem Laboratories Limited | 6.72 Billion INR | 84.029% |
Venus Remedies Limited | 1.91 Billion INR | 43.944% |
Wanbury Limited | 978.96 Million INR | -9.727% |
ZIM Laboratories Limited | 1.01 Billion INR | -6.034% |
Lupin Limited | 125.09 Billion INR | 99.141% |
Innova Captab Limited | 931.03 Million INR | -15.376% |
Ind-Swift Limited | 946.56 Million INR | -13.482% |
Bajaj HealthCare Limited | 985.34 Million INR | -9.016% |
Aurobindo Pharma Limited | 55.65 Billion INR | 98.07% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 57.943% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 56.572% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -562.146% |
Morepen Laboratories Limited | 1.98 Billion INR | 45.952% |
Laurus Labs Limited | 11.9 Billion INR | 90.981% |
Aarti Drugs Limited | 1.16 Billion INR | 7.991% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 90.772% |
Alembic Limited | 872.45 Million INR | -23.122% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 93.231% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 97.712% |
Vaishali Pharma Limited | 84.02 Million INR | -1178.352% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 65.06% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -144.94% |
Jubilant Pharmova Limited | 14.45 Billion INR | 92.568% |
Eris Lifesciences Limited | 4.94 Billion INR | 78.268% |
Windlas Biotech Limited | 1 Billion INR | -6.724% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.303% |
Orchid Pharma Limited | 800.77 Million INR | -34.144% |
Albert David Limited | 1.02 Billion INR | -4.681% |
Hester Biosciences Limited | 908.84 Million INR | -18.193% |
Sakar Healthcare Limited | 204.07 Million INR | -426.358% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 23.425% |
Procter & Gamble Health Limited | 2.99 Billion INR | 64.139% |
Divi's Laboratories Limited | 14.17 Billion INR | 92.419% |
Mankind Pharma Limited | 29.27 Billion INR | 96.33% |
Neuland Laboratories Limited | 2.92 Billion INR | 63.335% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 92.738% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.142% |
Wockhardt Limited | 8.48 Billion INR | 87.333% |
Bal Pharma Limited | 555.62 Million INR | -93.329% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.88% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 24.312% |
Alkem Laboratories Limited | 32.83 Billion INR | 96.729% |
Valiant Laboratories Limited | 138.02 Million INR | -678.232% |
Ajanta Pharma Limited | 30.46 Billion INR | 96.474% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | -135.782% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -7457.771% |
Granules India Limited | 10.31 Billion INR | 89.584% |
Medicamen Biotech Limited | 335.16 Million INR | -220.493% |
Ipca Laboratories Limited | 18.98 Billion INR | 94.343% |
Brooks Laboratories Limited | 51.18 Million INR | -1998.839% |
Syncom Formulations (India) Limited | 345.63 Million INR | -210.788% |
Piramal Enterprises Limited | 63.65 Billion INR | 98.312% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.986% |
NATCO Pharma Limited | 10.05 Billion INR | 89.32% |
Suven Life Sciences Limited | 109.75 Million INR | -878.757% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2227.294% |
Strides Pharma Science Limited | 9.16 Billion INR | 88.276% |
Indoco Remedies Limited | 12.06 Billion INR | 91.094% |
Alpa Laboratories Limited | 127.38 Million INR | -743.293% |
Lasa Supergenerics Limited | 291.17 Million INR | -268.915% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 65.088% |